# Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

> **NCT00078403** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 333 (actual)

## Conditions studied

- HIV Infections
- Hepatitis C
- Liver Disease

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00078403
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-05
- **Final completion:** 2009-02
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078403, "Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00078403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*